Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal CD8+ T Cells for Leptomeningeal Melanoma
NCT07414979Phase 1Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2026
- Primary completion
- Mar 2028
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous CD8+ antigen-specific T cells in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Adverse Events at 1 year. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
autologous CD8+ antigen-specific T cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07414979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07414979.